Literature DB >> 28293026

Therapy: The role of liquid biopsies to manage and predict PRRT for NETs.

Mark Kidd1, Irvin M Modlin2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28293026     DOI： 10.1038/nrgastro.2017.26

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status.

Authors:  Mark Kidd; Ignat Drozdov; Irvin Modlin
Journal:  Endocr Relat Cancer       Date:  2015-06-02       Impact factor: 5.678

2.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

3.  Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.

Authors:  Samer Ezziddin; Amir Sabet; Florian Heinemann; Charlotte J Yong-Hing; Hojjat Ahmadzadehfar; Stefan Guhlke; Tobias Höller; Winfried Willinek; Christian Boy; Hans-Jürgen Biersack
Journal:  J Nucl Med       Date:  2011-07-15       Impact factor: 10.057

Review 4.  Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Authors:  Dik J Kwekkeboom; Boen L Kam; Martijn van Essen; Jaap J M Teunissen; Casper H J van Eijck; Roelf Valkema; Marion de Jong; Wouter W de Herder; Eric P Krenning
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

7.  Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.

Authors:  L Bodei; M Kidd; I M Modlin; S Severi; I Drozdov; S Nicolini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

8.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

9.  The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.

Authors:  Irvin M Modlin; Ignat Drozdov; Mark Kidd
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240
  9 in total
  6 in total

1.  EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.

Authors:  James Saller; Shabnam Seydafkan; Mohammad Shahid; Manoj Gadara; Mauro Cives; Steven A Eschrich; David Boulware; Jonathan R Strosberg; Nasir Aejaz; Domenico Coppola
Journal:  Cancer Genomics Proteomics       Date:  2019 Sep-Oct       Impact factor: 4.069

2.  PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.

Authors:  Lisa Bodei; Mark S Kidd; Aviral Singh; Wouter A van der Zwan; Stefano Severi; Ignat A Drozdov; Jaroslaw Cwikla; Richard P Baum; Dik J Kwekkeboom; Giovanni Paganelli; Eric P Krenning; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-26       Impact factor: 9.236

3.  PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.

Authors:  Lisa Bodei; Mark S Kidd; Aviral Singh; Wouter A van der Zwan; Stefano Severi; Ignat A Drozdov; Anna Malczewska; Richard P Baum; Dik J Kwekkeboom; Giovanni Paganelli; Eric P Krenning; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-14       Impact factor: 9.236

Review 4.  Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.

Authors:  Martine Bocchini; Fabio Nicolini; Stefano Severi; Alberto Bongiovanni; Toni Ibrahim; Giorgia Simonetti; Ilaria Grassi; Massimiliano Mazza
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244

Review 5.  The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.

Authors:  Anna Malczewska; Beata Kos-Kudła; Mark Kidd; Ignat Drozdov; Lisa Bodei; Somer Matar; Kjell Oberg; Irvin M Modlin
Journal:  Adv Med Sci       Date:  2019-12-13       Impact factor: 3.287

6.  The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors.

Authors:  Jason Chia-Hsun Hsieh; Guan-Yu Chen; David Da-Wei Jhou; Wen-Chi Chou; Chun-Nan Yeh; Tsann-Long Hwang; Hung-Chi Lin; Hui-Chun Chu; Hung-Ming Wang; Tzu-Chen Yen; Jen-Shi Chen; Min-Hsien Wu
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.